Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia이전에 항-CD20 단일클론 항체 매개 B 세포 고갈 및 만성 림프구성 백혈병이 있는 환자에서 장기간 바이러스 SARS-CoV-2 복제에 대한 성공적인 구조 치료제로서의 플리티뎁신Case Reports Published on 2022-01-102022-09-10 Journal: Journal of Hematology & Oncology [Category] SARS, 바이오마커, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 affected anti-CD20 Anti-CD20 monoclonal antibody Antiviral antiviral drug antiviral therapies antiviral therapy B cell CD19 CD20 chronic lymphocytic leukemia compassionate use coronavirus coronavirus disease Course COVID-19 COVID-19 pneumonia deficiency develop hematological Hematological malignancies Host immune Immune deficiencies Immunosuppressed Infection leukemia Lymphocytic leukemia male monoclonal monoclonal antibodies Patient Plitidepsin Pneumonia Population Prolonged viral replication resolved respiratory SARS-CoV-2 SARS-CoV-2 patient SARS-CoV-2 patients SARS-CoV-2 replication Severe COVID-19 pneumonia supplementary material Support toxicities treated Treatment treatment with anti-CD20 undetectable Viral Viral load [DOI] 10.1186/s13045-021-01220-0 PMC 바로가기 [Article Type] Case Reports
Belatacept Use after Kidney Transplantation and Its Effects on Risk of Infection and COVID-19 Vaccine ResponseReview Published on 2021-11-032022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] addition Area belatacept CD80/CD86 CMV CNI COVID-19 COVID-19 infection cytomegalovirus database de novo disease Effect eight expert greater Immunosuppression immunosuppressive immunosuppressive regimen Impact increased risk kidney Kidney transplantation mechanism Older opportunistic Infections Patient Pneumonia receiving recipient respond poorly response risk risk of infection safety profile SARS-CoV-2 vaccination therapy toxicities transplantation Vaccines [DOI] 10.3390/jcm10215159 PMC 바로가기 [Article Type] Review
NICEdrug.ch, a workflow for rational drug design and systems-level analysis of drug metabolismTools and Resources Published on 2021-08-032022-10-31 Journal: eLife [Category] COVID-19, [키워드] alleviate Analysis anticancer candidate drug Cell COVID-19 database dataset drug drug clustering drug design drug metabolic fate drug similarity E. coli enzyme Enzyme inhibition evaluate explain golden standard high risk Human human host identify include inhibitory Intensive ligand-based drug discovery malaria mechanism metabolism metabolite nutraceuticals P. falciparum reactive reactivity reduce Research resource Side effects similarity small molecule targets toxicities Toxicity unique [DOI] 10.7554/eLife.65543 PMC 바로가기 [Article Type] Tools and Resources
Abbreviated Profile of Drugs (APOD): modeling drug safety profiles to prioritize investigational COVID-19 treatmentsResearch article Published on 2021-07-282022-10-05 Journal: Heliyon [Category] 신약개발, 치료법, 치료제, [키워드] Abbreviated Profile of Drugs (APOD) ADMET administer Analysis APOD approved approved drug Cancer category clinical development clinical trial coronavirus disease COVID-19 COVID-19 treatment criteria database dataset demonstrated Dexamethasone drug Drug discovery Drug safety profile effective EIDD-2801 examined facilitated FDA food GDC-0941 imperative inhibitors methodology moderate molnupiravir organ-specific P450 Pharmacokinetic prediction profile progression recalled resources safety profile tested toxicities transmitted Transport withdrawn [DOI] 10.1016/j.heliyon.2021.e07666 [Article Type] Research article
Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyondIII기 NSCLC 환자를 위한 2주 및 4주 보조제 durvalumab의 안전성 모니터링: COVID-19 범유행 및 그 이후에 미치는 영향Article Published on 2021-06-012022-09-12 Journal: Lung cancer (Amsterdam, Netherlands) [Category] MERS, SARS, 진단, [키워드] adjuvant Adjuvant durvalumab analysed approved Autoimmune disease blood tests Cancer carried clinical COVID-19 COVID-19 pandemic durvalumab hospital Immunotherapy implication NSCLC. observé pandemic Patient patients treated receiving Retrospective study risk factor Safety SARS-CoV-2 stage III Support survival toxicities Toxicity treated two groups [DOI] 10.1016/j.lungcan.2021.04.021 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study암 환자를 위한 COVID-19 백신 BNT162b2의 1회 투여 대 2회 투여의 안전성 및 면역원성: 전향적 관찰 연구의 중간 분석Observational Study Published on 2021-06-012022-09-10 Journal: The Lancet. Oncology [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] 95% CI Administered All participant All participants analysed analyses anti-S IgG antibody available data Blood blood sample Blood samples BNT162b2 BNT162b2 vaccine boost Cancer Cancer Research UK Cohort college COVID-19 COVID-19 vaccine Data analysis death dose Efficacy Efficacy and safety eight Endpoint enrolled Evidence evidence of exclusion finding first dose first vaccination FIVE Follow-up Francis Crick funding Haematological cancer Health and Care Research Wales Health Research Authority health-care healthy control healthy controls healthy controls; hospital immunogenicity immunogenicity analysis injection Injection-site pain interim analysis intramuscularly King local reaction London nasopharyngeal NHS observational study of BNT162b2 Pain participant Patient Patients with cancer patients with haematological Pfizer–BioNTech positive profile proportion prospective observational study Protein real-time RT-PCR REC receive recruited Registered reported rRT-PCR Safety SARS-CoV-2 SARS-CoV-2 spike second dose Seroconversion seropositive significantly single vaccine solid cancer Support Swab test symptomatic symptomatic COVID-19 the patient titre toxicities Toxicity Trust vaccination Vaccine Wellcome Trust [DOI] 10.1016/S1470-2045(21)00213-8 PMC 바로가기 [Article Type] Observational Study
SARS-CoV-2 Disinfection of Air and Surface Contamination by TiO 2 Photocatalyst-Mediated Damage to Viral Morphology, RNA, and ProteinArticle Published on 2021-05-202022-10-28 Journal: Viruses [Category] COVID-19, SARS, [키워드] absence adverse effect aerosol Aerosols Compound contaminated surface COVID-19 damage decrease disease-causing Disinfection Effect effective for disinfection Genome global pandemic Health Human infectious agents Radiation reduced RNA RNA damage RT-qPCR SARS-CoV-2 SARS-CoV-2 inactivation Spread surface TiO2 photocatalyst toxicities transmission electron microscopy transmitted Treatment ultraviolet C viral morphology disruption Viral protein viral protein damage virion virus [DOI] 10.3390/v13050942 PMC 바로가기 [Article Type] Article
Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapyCOVID-19 및 암 면역 요법에서 공유된 염증 경로 및 치료 전략Article Published on 2021-05-012022-09-12 Journal: Journal for immunotherapy of cancer [Category] SARS, 진단, [키워드] acute respiratory distress adverse event Allogeneic anti-inflammatory drug Anti-inflammatory therapy antibody Antigen approach ARDS benefit Cancer immunotherapy caused Cell cells characterized chimeric circulating cytokines clinical trial Complication coronavirus COVID-19 CRS cytokine disease drug drugs Effect elevated Endothelial dysfunction exaggerated immune response Graft-versus-host disease help Hospitalization immune system Immunotherapy infection with SARS-CoV-2 Inflammation Inflammation mediators Inflammatory inflammatory pathway inhibiting interleukin-6 interstitial involved mechanism monoclonal antibody Mortality pathogenesis of COVID-19 pathway performed preliminary evidence reducing reduction in SARS-COV-2 infection stimulate suppress syndrome systematic review systemic manifestation therapeutic strategy therapy toxicities Toxicity Treatment trials triggered viral infection [DOI] 10.1136/jitc-2021-002392 PMC 바로가기 [Article Type] Article
Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated ToxicityPharmacology Published on 2021-04-122022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] “cytokine storm” added Against age anti-SARS-CoV-2 Antiviral mechanism approved Attention Autoimmune diseases autophagy Cancer Chloroquine clinical trial derivative Diseases dosage Effect FDA immunomodulatory in vitro in vivo inhibit interfere malaria mechanism Multiple pandemic of COVID-19 pH-dependent Randomized Receptor binding Replication repurposing SARS-CoV-2 seeking shown Side-effects toxicities Toxicity trans-Golgi network treat Trial viral disease Viral diseases Viral particles [DOI] 10.3389/fphar.2021.576093 PMC 바로가기 [Article Type] Pharmacology
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment신장 및 간 장애 환자의 용도 변경 COVID-19 약물 투여에 대한 권장 사항Review Published on 2021-03-012022-09-11 Journal: Drugs in R&D [Category] MERS, 신약개발, 임상, 치료제, [키워드] acute infection acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Affect Altered Anakinra anticipated Antiviral Atazanavir available data Azithromycin clinician complex coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 in patient Dexamethasone Dosing drug drug concentration drug concentrations drug interaction Efficacy excretion experimental drug Experimental drugs Favipiravir Guidance hepatic hepatic disease hepatic function hepatic impairment Hydroxychloroquine immune indications Injury interferon beta Limited Lopinavir Lopinavir/ritonavir medication medications metabolism outbreak Patient patients with COVID-19 pharmacokinetic pharmacokinetics produced recommendation reduced regimen Remdesivir renal renal or hepatic impairment respiratory resulting ribavirin Ritonavir sarilumab SARS-CoV-2 significantly therapy Tocilizumab toxicities Toxicity treat Treatment treatment for COVID-19 Trial University of Liverpool Variability was performed website [DOI] 10.1007/s40268-020-00333-0 PMC 바로가기 [Article Type] Review